Optimising mRNA Manufacturing & Process Development to Accelerate Time to Market for Disease X & Beyond
Time: 3:00 pm
day: Day Two
Details:
- How to leverage existing knowledge from established vaccine families and data, to optimise preparedness and streamline process development for new disease indications or in response to Disease X?
- How can the transition from batch to continuous manufacturing eliminate the need for traditional scale-up by adjusting production run times to meet diverse therapeutic demands, from personalised therapies to large-scale pandemic responses?
- How can challenges such as process initialisation, step synchronisation, and realtime quality monitoring during the transition from batch to continuous manufacturing be addressed to ensure consistent operation, enhance scalability, and accelerate timelines?
